Teva launches authorized generics: Actos, ACTOplus met

August 21, 2012

Teva Pharmaceutical Industries Ltd has launched authorized generics of products indicated for use with diet and exercise to improve blood glucose control in adults with type 2 diabetes.

Teva Pharmaceutical Industries Ltd has launched an authorized generic (AG) of Actos (pioglitazone hydrochloride tablets) in 15-mg, 30-mg, and 45-mg dose strengths, as well as an AG of ACTOplus met (pioglitazone/metformin tablets) in 15 mg/500 mg and 15 mg/850 mg dose strengths. Both products are indicated for use with diet and exercise to improve blood glucose control in adults with type 2 diabetes.

Actos and ACTOplus met are marketed by Takeda Pharmaceuticals U.S.A.

The brand product, Actos, had annual sales of approximately $2.7 billion in the United States, and the combination product, ACTOplus met, had annual sales totaling $413 million in the United States, according to IMS sales data as of June 30, 2012.